TAS Minutes 27th February 2024(236 KB) - TAS
Date added: 28th Mar 2024
Drug Name | Classification | Clinical Indication | Comments |
---|---|---|---|
ACETYLCYSTEINE NEBULISED | Red | Last line mucolytic treatment to loosen tenacious secretions. Under supervision of a senior respiratory physiotherapist only. | |
Azathioprine 75mg & 100mg | Do not prescribe | Autoimmune Conditions |
Increased risk of medication errors with 75mg and 100mg tablets. Use 25mg and 50mg tablets only. |
BELUMOSUDIL (Rezurock®) (NEW) | Red | For treating chronic graft-versus host disease after 2 or more systemic treatments in people 12 years and over. | |
BUDESONIDE/ FORMOTEROL FUMARATE DIHYDRATE INHALER (GoResp Digihaler®) (UPDATED) | Red | Asthma & COPD |
Restricted to severe asthma clinic only on a named patient basis |
DORNASE ALFA (UPDATED) | Red | Cystic fibrosis |
Red; all new patients. Yellow status for existing patients where patients are already in primary care |
DORNASE ALFA | Red | Pleural Infections | |
HYBRID CLOSED LOOP (NEW) | Red | Diabetes Glucose Monitoring & Delivery System |
In line with NICE TA943 |
HYPERTONIC SODIUM CHLORIDE, NEBULISED | Yellow | To loosen tenacious secretions. Under supervision of a respiratory physiotherapist. |
Available as 3% and 7% solutions. |
IBUPROFEN MR (NEW) | Red | Stat doses prior to day case surgery | |
NEFOPAM (UPDATED) | Yellow | Pain |
Initiation restricted on advice of secondary care pain team only. Historic patients may continue therapy as appropriate. |
PROBENECID | Red | Prevention of nephrotoxicity associated with cidofovir treatment | |
PROGESTERONE (Gepretix®) (UPDATED) | Green | For adjunctive use with an oestrogen in post-menopausal women with an intact uterus, as hormone replacement therapy (HRT). | |
SACUBITRIL and VALSARTAN (Entresto®) | Yellow | Heart failure |
For background and information and monitoring requirements, (in line with ACEI/ARB monitoring for heart failure), please see interim information whilst the heart failure guide is being updated.
|
SACUBITRIL AND VALSARTAN (Entresto®) (NEW) | Red | Paediatric heart failure | |
TARGETED-RELEASE BUDESONIDE (NEW) | Red | for treating primary IgA nephropathy |
In line with NICE TA937 |
TROPOLONE (NEW) | Red | Platelet labelling in nuclear medicine |
Recent documents from LLR APC and TAS
Date added: 28th Mar 2024
Date added: 28th Mar 2024
Date added: 27th Mar 2024
Version 1 Uploaded March 2024
Date added: 25th Mar 2024
Version 1 Uploaded March 2024
Date added: 25th Mar 2024
Version 1 Uploaded March 2024
Date added: 20th Mar 2024
Version 1 Uploaded March 2024
Date added: 20th Mar 2024
Version 1 Uploaded March 2024
Date added: 20th Mar 2024
Version 3.0 Uploaded March 2024
Date added: 12th Oct 2020
Version 3.9 Uploaded March 2024
Date added: 14th Aug 2018
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more